Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Research shows that glucagon-like peptide-1 receptor agonists (or GLP-1s – think Ozempic or similar medications) are changing ...

The issuer is solely responsible for the content of this announcement.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Unlock the latest advancements in obesity treatment. Expert insights reveal groundbreaking medical breakthroughs and ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Wegovy is a prescription medication designed for chronic weight management, offering hope to individuals struggling with ...

A WOMAN has revealed the bizarre transformation that took place after going on weight loss jabs – and it wasn’t her body. Amy ...